Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 19 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Alembic Pharmaceuticals Ltd

About the Company - Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5035.41 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAlembic Road, Vadodra Gujarat 390003apl.investors@alembic.co.in
http://www.alembicpharmaceuticals.com
Management
NamePosition Held
Mr. Chirayu AminChairman & CEO
Mr. Pranav AminManaging Director
Mr. Shaunak AminManaging Director
Mr. R K BahetiDirector - Finance & CFO
Dr. Archana HingoraniIndependent Director
Mr. Ashok BaratIndependent Director
Mr. Jai DiwanjiIndependent Director
Mr. Manish KejriwalIndependent Director

Basic Stock Data of Alembic Pharmaceuticals Ltd

Last Updated: July 18, 2024, 11:25 pm

Market Cap 21,160 Cr.
Current Price 1,077
High / Low1,119/662
Stock P/E34.5
Book Value 245
Dividend Yield1.02 %
ROCE13.1 %
ROE13.3 %
Face Value 2.00
PEG Ratio-3.73

Data Source: screener.in

Competitors of Alembic Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Mangalam Drugs and Organics Ltd 166 Cr. 105132/85.2 89.90.00 %1.19 %6.15 % 10.0
SMS Pharmaceuticals Ltd 2,040 Cr. 240265/10541.3 67.40.12 %11.2 %9.28 % 1.00
Pfizer Ltd 23,242 Cr. 5,0845,173/3,80042.6 7860.69 %21.9 %16.0 % 10.0
Concord Drugs Ltd 38.3 Cr. 38.361.5/25.691.1 33.80.00 %4.54 %1.29 % 10.0
Dr Reddys Laboratories Ltd 1,11,282 Cr. 6,6686,885/5,20620.2 1,6940.60 %26.5 %21.4 % 5.00
Industry Average16,955.18 Cr1,323.2247.34208.390.34%17.27%16.45%6.53

Alembic Pharmaceuticals Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales1,3141,2801,3261,2921,2721,4161,2621,4751,5091,4061,4861,5951,631
Expenses9499601,0901,0541,0301,2681,2551,2441,2741,2031,2871,3871,364
Operating Profit3653202362392421487231235204199208266
OPM %28%25%18%18%19%10%1%16%16%14%13%13%16%
Other Income3252211910100112103
Interest2325479121514141615
Depreciation475153555612367686774666869
Profit before tax31829218320020129-67151154116130135185
Tax %19%19%19%20%14%24%2%12%21%-31%7%-1%2%
Net Profit28624215816417222-66133122153121137180
EPS in Rs14.8812.758.378.348.741.12-3.356.786.207.766.146.959.18

Last Updated: July 10, 2024, 2:50 pm

Alembic Pharmaceuticals Ltd Quarterly Chart

Alembic Pharmaceuticals Ltd Profit & Loss

Last Updated: July 10, 2024, 2:50 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,4651,5201,8632,0563,1663,1053,1313,9354,6065,3935,3065,6535,997
Expenses1,2461,2681,5061,6532,1592,4902,4883,0613,3833,9134,4324,9705,151
Operating Profit2192523584031,0076156438741,2231,480874682845
OPM %15%17%19%20%32%20%21%22%27%27%16%12%14%
Other Income134447279-398756-223
Interest3815104553182716185059
Depreciation343540447283105115157183287275274
Profit before tax1612063113599365295417491,0001,368625355535
Tax %19%20%24%21%23%23%22%21%20%19%17%4%
Net Profit1301652362837204034135838011,146521342532
EPS in Rs6.908.7712.4915.0138.2021.3921.8931.0043.9758.3326.5017.4027.05
Dividend Payout %20%29%24%23%9%19%18%18%23%24%38%46%

Alembic Pharmaceuticals Ltd Profit & Loss Yearly Chart

Alembic Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:13%
5 Years:10%
3 Years:5%
TTM:10%
Compounded Profit Growth
10 Years:10%
5 Years:1%
3 Years:-19%
TTM:77%
Stock Price CAGR
10 Years:12%
5 Years:16%
3 Years:4%
1 Year:63%
Return on Equity
10 Years:20%
5 Years:16%
3 Years:10%
Last Year:13%

Last Updated: July 17, 2024, 5:59 pm

Alembic Pharmaceuticals Ltd Balance Sheet

Last Updated: July 10, 2024, 2:50 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital38383838383838383839393939
Reserves3574656388471,5601,8652,1822,6813,1825,0285,1984,3314,431
Borrowings353187109264114897081,1281,747584717722869
Other Liabilities3043584324937186981,0139311,0221,0581,1671,0901,116
Total Liabilities1,0521,0481,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,455
Fixed Assets2683443975477087999931,1581,5521,7881,7982,3982,603
CWIP58322183933961,0101,5511,8462,1832,304601478
Investments333287504249182361189698
Other Assets7236687961,0091,5411,4441,8962,0192,5732,5022,9023,0873,277
Total Assets1,0521,0481,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,455

Alembic Pharmaceuticals Ltd Reserves and Borrowings Chart

Alembic Pharmaceuticals Ltd Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 2652401729483293128124491,463552724803
Cash from Investing Activity -67-81-256-307-486-884-756-731-840-372-448-321
Cash from Financing Activity -229-15187-224-12950359155-597-217-262-438
Net Cash Flow-3183417-286-69115-12726-371445

Alembic Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days505654644040614569245668
Inventory Days133143159196266269302356417431406315
Days Payable108129148166264213313237220194178145
Cash Conversion Cycle75706594429651164266261283237
Working Capital Days615950714972936411894118119
ROCE %30%31%44%38%66%29%22%23%24%26%11%7%

Alembic Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Alembic Pharmaceuticals Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters69.48%69.48%69.48%69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.61%
FIIs6.41%5.52%5.89%6.02%5.94%5.32%4.99%4.55%4.34%4.51%4.52%4.46%
DIIs11.25%11.42%11.61%11.74%12.15%12.55%12.76%13.32%13.65%14.22%14.51%15.39%
Public12.86%13.58%13.03%12.63%12.30%12.52%12.64%12.53%12.39%11.67%11.36%10.54%
No. of Shareholders1,01,6861,23,0591,10,0381,06,4371,01,4571,03,8111,01,86499,52297,60789,55285,21276,567

Alembic Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Alembic Pharmaceuticals Ltd Shareholders

Alembic Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
DSP Mid Cap Fund4,766,0712.23355.45235,6522024-07-181922.5%
Kotak Small Cap Fund - Regular Plan3,874,0162.16288.92235,6522024-07-181543.96%
DSP ELSS Tax Saver Fund1,727,1231.02128.81235,6522024-07-18632.91%
DSP Healthcare Fund1,346,0665.22100.39235,6522024-07-18471.21%
DSP Small Cap Fund766,1180.4457.14235,6522024-07-18225.11%
DSP Top 100 Equity Fund701,7551.6652.34235,6522024-07-18197.79%
Aditya Birla Sun Life Small Cap Fund515,6650.7738.46235,6522024-07-18118.82%
Axis Small Cap Fund235,6520.117.57235,6522024-07-180%
Mahindra Manulife Flexi Cap Fund170,0001.1712.68235,6522024-07-18-27.86%
Aditya Birla Sun Life Pharma & Healthcare Fund161,1382.1312.02235,6522024-07-18-31.62%

Alembic Pharmaceuticals Ltd ROCE Trend

Alembic Pharmaceuticals Ltd EPS Trend

Alembic Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)17.4026.5060.8143.9731.00
Diluted EPS (Rs.)17.4026.5060.8143.9731.00
Cash EPS (Rs.)32.9940.8366.0550.8237.55
Book Value[Excl.RevalReserv]/Share (Rs.)222.36266.47257.80169.25144.19
Book Value[Incl.RevalReserv]/Share (Rs.)222.36266.47257.80169.25144.19
Revenue From Operations / Share (Rs.)287.59269.95274.39244.34208.74
PBDIT / Share (Rs.)36.1847.0479.7565.1446.84
PBIT / Share (Rs.)22.1732.4570.4256.8040.73
PBT / Share (Rs.)19.6131.5569.6053.0439.75
Net Profit / Share (Rs.)18.9726.2356.7242.4731.44
NP After MI And SOA / Share (Rs.)17.4026.5059.9443.9731.00
PBDIT Margin (%)12.5817.4229.0626.6622.44
PBIT Margin (%)7.7012.0225.6623.2419.51
PBT Margin (%)6.8211.6825.3621.7019.04
Net Profit Margin (%)6.599.7120.6717.3815.06
NP After MI And SOA Margin (%)6.059.8121.8417.9914.85
Return on Networth / Equity (%)7.829.9422.9725.7421.49
Return on Capital Employeed (%)9.5811.7925.4925.2623.34
Return On Assets (%)5.537.3117.5613.8312.23
Long Term Debt / Equity (X)0.000.000.030.270.18
Total Debt / Equity (X)0.140.120.030.540.34
Asset Turnover Ratio (%)0.770.730.790.770.86
Current Ratio (X)1.781.672.011.411.31
Quick Ratio (X)0.870.720.850.720.66
Inventory Turnover Ratio (X)0.860.780.930.951.05
Dividend Payout Ratio (NP) (%)57.4752.820.0039.3215.55
Dividend Payout Ratio (CP) (%)31.8334.060.0033.0512.99
Earning Retention Ratio (%)42.5347.180.0060.6884.45
Cash Earning Retention Ratio (%)68.1765.940.0066.9587.01
Interest Coverage Ratio (X)14.1752.1597.8545.2147.96
Interest Coverage Ratio (Post Tax) (X)8.4330.0870.5932.0933.19
Enterprise Value (Cr.)10301.5015131.7919003.4511697.0810722.89
EV / Net Operating Revenue (X)1.822.853.522.542.73
EV / EBITDA (X)14.4916.3712.129.5312.14
MarketCap / Net Operating Revenue (X)1.722.753.522.182.54
Retention Ratios (%)42.5247.170.0060.6784.44
Price / BV (X)2.232.783.703.123.68
Price / Net Operating Revenue (X)1.722.753.522.182.54
EarningsYield0.030.030.060.080.05

Alembic Pharmaceuticals Ltd Profitability Ratios (%)

Alembic Pharmaceuticals Ltd Liquidity Ratios

Alembic Pharmaceuticals Ltd Liquidity Ratios (%)

Alembic Pharmaceuticals Ltd Interest Coverage Ratios (%)

Alembic Pharmaceuticals Ltd Valuation Ratios

Strength and Weakness of Alembic Pharmaceuticals Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 29.25%, which is a positive sign.
  2. The company has higher reserves (2,729.67 cr) compared to borrowings (573.50 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (3.15 cr) and profit (408.38 cr) over the years.
  1. The stock has a high average Working Capital Days of 80.67, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 142.00, which may not be favorable.

FAQ

What is the latest fair value of Alembic Pharmaceuticals Ltd?

The latest fair value of Alembic Pharmaceuticals Ltd is ₹950.51.

What is the Market Cap of Alembic Pharmaceuticals Ltd?

The Market Cap of Alembic Pharmaceuticals Ltd is 21,160 Cr..

What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 19 July 2024?

The current stock price of Alembic Pharmaceuticals Ltd as on 19 July 2024 is 1,077.

What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2024?

In FY 2024, the High / Low of Alembic Pharmaceuticals Ltd stocks is 1,119/662.

What is the Stock P/E of Alembic Pharmaceuticals Ltd?

The Stock P/E of Alembic Pharmaceuticals Ltd is 34.5.

What is the Book Value of Alembic Pharmaceuticals Ltd?

The Book Value of Alembic Pharmaceuticals Ltd is 245.

What is the Dividend Yield of Alembic Pharmaceuticals Ltd?

The Dividend Yield of Alembic Pharmaceuticals Ltd is 1.02 %.

What is the ROCE of Alembic Pharmaceuticals Ltd?

The ROCE of Alembic Pharmaceuticals Ltd is 13.1 %.

What is the ROE of Alembic Pharmaceuticals Ltd?

The ROE of Alembic Pharmaceuticals Ltd is 13.3 %.

What is the Face Value of Alembic Pharmaceuticals Ltd?

The Face Value of Alembic Pharmaceuticals Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Alembic Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE